Fredag 26 Juni | 20:25:00 Europe / Stockholm
Est. tid*
2026-11-12 07:00 Kvartalsrapport 2026-Q3
2026-08-19 07:00 Kvartalsrapport 2026-Q2
2026-05-15 - Kvartalsrapport 2026-Q1
2026-04-24 - X-dag ordinarie utdelning LIFE 0.00 NOK
2026-04-23 - Årsstämma
2026-03-03 - Bokslutskommuniké 2025
2026-01-02 - Extra Bolagsstämma 2026
2025-11-12 - Extra Bolagsstämma 2025
2025-11-12 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-15 - Kvartalsrapport 2025-Q1
2025-04-28 - X-dag ordinarie utdelning LIFE 0.00 NOK
2025-04-25 - Årsstämma
2025-02-20 - Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018
LandNorge
ListaOslo Bors
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av microsensorer för diabetes. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

LIFE: Operational update regarding Lifecare Germany GmbH (i.L)

2026-06-26 17:30:00

Bergen, Norway, 26 June 2026 – Lifecare ASA ("Lifecare") provides the following update regarding the wind-down of its wholly owned subsidiary, Lifecare Germany GmbH (i.L.).

Reference is made to Lifecare's announcement of 26 March 2026 regarding the strategic decision to discontinue the operations of Lifecare Germany GmbH as part of the Group's operational restructuring and the centralization of manufacturing and development activities to Bergen, Norway, and Bristol, United Kingdom.

The operational restructuring has been implemented in accordance with the Company's previously communicated plan.

Since that announcement, the Company has completed the operational transition from Germany. Manufacturing activities, personnel, equipment, know-how and key development activities have been transferred or are in the process of being transferred in accordance with the Group's restructuring plan.

During the ongoing liquidation process, management has continued to assess the remaining obligations and financial position of Lifecare Germany GmbH. Following this assessment, and in accordance with applicable German legislation and the directors' statutory duties, management has concluded that the liquidation process should be continued through formal insolvency proceedings. Consequently, a filing has been submitted to the competent German court today.

The continued proceedings will not have any material negative impact on Lifecare's financial position, ongoing operations, product development activities, regulatory programmes, manufacturing strategy or previously communicated outlook. The operational restructuring announced in March 2026 has already been substantially implemented, and all operating activities are now conducted in Norway and the UK and no additional funding will be provided by Lifecare ASA to Lifecare Germany GmbH (i.L).

Lifecare will in the continuation fully cooperate with relevant authorities and any appointed administrator and will provide further updates if required.